Point72 (Difc) LTD Cue Biopharma, Inc. Transaction History
Point72 (Difc) LTD
- $2.72 Trillion
- Q4 2024
A detailed history of Point72 (Difc) LTD transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Point72 (Difc) LTD holds 66 shares of CUE stock, worth $66. This represents 0.0% of its overall portfolio holdings.
Number of Shares
66
Previous 58
13.79%
Holding current value
$66
Previous $44,000
63.64%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CUE
# of Institutions
57Shares Held
11.9MCall Options Held
22KPut Options Held
1.2K-
Bleichroeder LP New York, NY5MShares$5.05 Million1.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.06MShares$2.08 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$764,3030.0% of portfolio
-
Geode Capital Management, LLC Boston, MA631KShares$637,5930.0% of portfolio
-
Robertson Stephens Wealth Management, LLC San Francisco, CA479KShares$483,2850.02% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $35.7M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...